Shanghai
Shanghai
Shanghai, Huangpu District, China6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| The Application of Electrical Stimulation in Postoperative Pain Management of Thyroid Surgery | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland carcinoma, thyroid gland disorder, thyroid tumor | Recruiting | Not applicable | 2026-08-19 | NCT06931743 | |
| Systemic Application of Cadonilimab, LM-302, and S-1 Combined With Intraperitoneal Infusion of Paclitaxel for the Treatment of Claudin 18.2-positive Gastric Cancer With Peritoneal Metastasis | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-07-29 | NCT06519591 | |
| Screening, Classification, and Outcome Prediction Ensemble Using Orbital MRI for Thyroid Eye Disease: The TED SCOPE National Multicenter Registry Study | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Recruiting | Not stated | 2026-07-21 | NCT07716397 | |
| Neoadjuvant Tislelizumab + LM-302 + S-1 or Tislelizumab + SOX for CLDN18.2-Positive Gastric/GEJ Adenocarcinoma | Gastric or Esophagogastric Junction Adenocarcinoma | Recruiting | Phase 2 | 2026-05-06 | NCT07569068 | |
| LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, gastric neoplasm, neoplasm, stomach disorder | Recruiting | Phase 2 | 2026-04-29 | NCT07556640 | |
| Safety and Efficacy Study of RXIM002 in Severe, Relapsed or Refractory Autoimmune Diseases | Disease Attributes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, autoimmune disease, immune system disorder | Recruiting | Early phase 1 | 2026-01-23 | NCT07322718 |